NCT03025282View on ClinicalTrials.gov

Safety and Efficacy of CD10367 in Psoriasis Vulgaris

PHASE2CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

November 3, 2016

Primary Completion Date

March 24, 2017

Study Completion Date

March 24, 2017

Conditions

Psoriasis Vulgaris

Interventions

DRUG

CD10367 3% Solution - Non-desquamated zone

Once daily application for 3 weeks

DRUG

CD10367 1% Solution - Non-desquamated zone

Once daily application for 3 weeks

DRUG

CD10367 solution placebo - Non-desquamated zone

Once daily application for 3 weeks

DRUG

Betneval ointment - Non-desquamated zone

Once daily application for 3 weeks

DRUG

CD10367 3% Solution - Desquamated zone

Once daily application for 3 weeks

DRUG

CD10367 solution placebo - Desquamated zone

Once daily application for 3 weeks

Trial Locations (1)

Unknown

Galderma Investigational Site, Nice

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Galderma R&D

INDUSTRY